- Home
- Companies
- SOPHiA Genetics
- Services
- SOPHiA DDM - BioPharma Solutions
SOPHiA DDM - BioPharma Solutions
Unlocking the potential of precision medicine with Artificial Intelligence – enabled data-driven insights. Advance targeted therapy development by harnessing the power of data and multimodal analytics. Advances in molecular and imaging techniques have resulted in an explosion of data, providing an unprecedented opportunity to identify clinically relevant drug targets. Yet, deciphering and extracting subtle biomarker signatures from multiple data modalities and sources remains challenging. The cloud-based and decentralized SOPHiA DDM™ Platform integrates data and algorithms, driving valuable insights to uncover biomarkers, identify requirement-matching cohorts, enhance clinical trial performance, and streamline the commercialization of new drugs.
Leveraging our unique AI expertise, SOPHiA GENETICS provides an unparalleled offering, unlocking insights from complex data types, driving faster discovery of new stratifying biomarkers, in addition to aiding in the commercialization of precision medicines (Fig. 1).
Real-World Data (RWD) Solutions
Providing insights from multimodal datasets across our global decentralized network
Multimodal Analytics
Stratifying populations using multimodal biomarkers through advanced analytics
Solution Development & Deployment
Development of clinical decision support solutions coupled with a decentralized deployment to enable commercialization of your asset
Figure 1: Strategic solutions offered by SOPHiA GENETICS for new therapies discovery, clinical trial development, and commercialization of emerging therapies.
SOPHiA GENETICS is a leader in multimodal analytics that drive the discovery of novel biomarker signatures for accurate patient stratification. Harnessing the power of advanced AI and machine learning, we unlock multimodal insights across a wide range of digital health data modalities. We generate high-quality genomics and radiomics data, and combine existing multimodal data sets using our 10+ organ-specific algorithms to identify potentially predictive or prognostic signatures (Fig. 2).
SOPHiA GENETICS provides a global perspective based on Real-World biomarker testing practices. Powered by multimodal datasets curated across 780+ hospitals worldwide, we have generated over 1.3 million genomic profiles* using SOPHiA DDM™ Platform, a cloud-based Software-as-a-Service platform covering Oncology as well as Rare and Inherited Disorders. The platform ensures data protection and respect national privacy laws, GDPR, HIPAA guidelines and applicable legislation regarding data protection.
Identify unmet medical needs and underserved patient groups early on your precision medicine journey. Shorten drug development timelines and reduce costs by leveraging SOPHiA DDM™ Platform to unlock biologically actionable insights from genomic and molecular epidemiology profiles, geographical distribution, and routine genetic testing practices.
Leverage Real-World Data to change the way you design clinical trials. Improve site selection, identify the right biomarkers and patient populations, and shorten enrollment cycles with on-demand access to the SOPHiA DDM™ Platform and its wealth of clinical data from across the globe.
SOPHiA DDM™ Awareness
Precision medicine targets a limited pool of biomarker-positive patients. Knowing if your target market tests for your biomarker of interest is critical for accurate commercial forecasts, efficient investments, and successful uptake of your precision therapies. Tap into SOPHiA DDM™ to quickly access a vast clinical research network and stay up to date with the rapidly-changing genetic testing landscape.
Global data-sharing network at your fingertips. Our networked platform with real-time flagging of positive biomarker profiles helps with:
- Finding the right sites for your clinical trials
- Real-time statistics on profiles that are relevant for specific therapies
- Insights on testing practices in the real-world
SOPHiA GENETICS recently announced the deployment of the cohort study Predictive Multimodal Signatures Associated with Response to Treatment and Prognosis of Patients with Stage IV Non-small Cell Lung Cancer (DEEP-Lung-IV); (NCT04994795). This large-scale, international, and multicentric real-world study is enrolling 4,000 patients from approximately 30 sites across North America, Europe, and Latin America.
The study leverages machine learning-enabled analysis of aggregated multimodal clinical, biological, genomics, and radiomics data to identify and validate predictive signatures associated with response to immunotherapy and prognosis of patients with metastatic non-small cell lung cancer (NSCLC). DEEP-Lung-IV aims to generate entirely novel insights to improve clinical outcomes for patients with stage IV NSCLC treated with immunotherapy and develop next-generation patient stratification strategies to support selecting the right patients for clinical trials.
